DEBIOPHARM LAUNCHES PHASE 1 RESEARCH IN SMALL CELL LUNG CANCER WITH WEE1 INHIBITOR DEBIO 0123 TO OUTSMART DDR IN SMALL CELL LUNG CANCER

The Debio 0123 program originates from a growing awareness of DDR inhibition in fighting life-threatening cancers. Optimizing efficacy, while preserving safety are key elements that Debiopharm is eager to assess throughout the clinical development of Debio 0123. With the fruition of these factors, Debio 0123 could become the first choice WEE1 inhibitor. The Debio 0123 program originates from a growing awareness of DDR inhibition in fighting life-threatening cancers. Optimizing efficacy, while...

Barcelona, Spain, 30/05/2023 (informazione.news - comunicati stampa - scienza e tecnologia)

 

 

Debiopharm aims to develop innovative therapies that target high unmet medical needs in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then select large pharmaceutical commercialization partners to maximize patient access globally. 

For more information, please visit www.debiopharm.com

We are on Twitter. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews  

Dawn Bonine
Head of Communications
dawn.bonine@debiopharm.com
Tel: +41 (0)21 321 01 11

 Rudin, C.M., Brambilla, E., Faivre-Finn, C. et al. Small-cell lung cancer. Nat Rev Dis Primers 7, 3 (2021). https://doi.org/10.1038/s41572-020-00235-0

 Paz-Ares, Luis et al. "Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer ( CASPIAN ): a randomised, controlled, open-label, phase 3 trial." Lancet ( London, England ) vol. 394,10212 (2019): 1929-1939. doi:10.1016/S0140-6736(19)32222-6

View original content:https://www.prnewswire.co.uk/news-releases/debiopharm-launches-phase-1-research-in-small-cell-lung-cancer-with-wee1-inhibitor-debio-0123-to-outsmart-ddr-in-small-cell-lung-cancer-301835814.html